We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ALXO market cap is 713.66M. The company's latest EPS is USD -3.2063 and P/E is -4.44.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -36.68M | -32.22M | -32.2M | -36.78M | -53.28M |
| Net Income | -35.32M | -30.71M | -30.18M | -34.16M | -50.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 4.8M | 1.18M | 0 | 0 | 0 |
| Operating Income | -19.18M | -43.66M | -83.56M | -127.44M | -170.28M |
| Net Income | -23.27M | -50.94M | -83.46M | -123.48M | -160.81M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 317.69M | 306.49M | 278.14M | 245.93M | 220.11M |
| Total Liabilities | 30.73M | 43.03M | 37.75M | 33.24M | 51.36M |
| Total Equity | 286.96M | 263.46M | 240.39M | 212.69M | 168.75M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 10.68M | 436.05M | 380.18M | 306.49M | 242.55M |
| Total Liabilities | 10.95M | 6.21M | 17.13M | 43.03M | 52.84M |
| Total Equity | -70.64M | 429.85M | 363.05M | 263.46M | 189.71M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -68.56M | -89.22M | -27.82M | -59.53M | -90.69M |
| Investing | -246.36M | -235.42M | 42.3M | 48.51M | 61.32M |
| Financing | 366k | 9.86M | -107k | 236k | 125k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -14.25M | -38.29M | -68.1M | -89.22M | -130.36M |
| Investing | -353k | 610k | -4.92M | -235.42M | 44.66M |
| Financing | 15.36M | 462.88M | 2.47M | 9.86M | 59.29M |
| Market Cap | 713.66M |
| Price to Earnings Ratio | -4.44 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 31.85 |
| Price to Book Ratio | 3.76 |
| Dividend Yield | - |
| Shares Outstanding | 50.15M |
| Average Volume (1 week) | 998.92k |
| Average Volume (1 Month) | 639.21k |
| 52 Week Change | 135.99% |
| 52 Week High | 17.42 |
| 52 Week Low | 3.9357 |
| Spread (Intraday) | 3.19 (19.68%) |
| Company Name | ALX Oncology Holdings Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.alxoncology.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
